Reduce Your Outsourcing Risk. Optimize Your Outcomes.
Developing an outsourced contract manufacturing strategy, coupled with negotiating, selecting and managing the right contract manufacturing organization (CMO) is a specialized task.
At NegotiumBio we support pharmaceutical and life science companies in executing outsourced manufacturing and procurement strategies across diverse modalities. Our successful negotiation track record includes small and large molecules as well as cell & gene therapies, including CAR-T, TCR, viral vector, plasmid, mAB, protein, and CRISPR based therapies.
Whatever modality your drug may be, we’ve got you covered in terms of identifying and mitigating outsourcing risks and maximizing cost effectiveness – helping you make the deal that best leverages your resources.
Through a new strategic partnership, we are now expanding our offering, providing AI-driven tailor-made business and technology development solutions to our customers in the pharma and life science sector.
NegotiumBio supports pharmaceutical and biotechnology innovator programs across all modalities - small and large molecules, cell and gene therapies.
Examples of recent projects, demonstrating the time and money our clients saved by putting NegotiumBio at the center of their negotiation process.